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Abstract
Introduction: Women are increasingly having children at a later age, but
this can conflict with declining fertility in the later 30′s and thereafter.
Areas of agreement: Declining egg quality and quantity with age are well-
established, although egg quality can only be surmised from reproductive
success or failure.
Areas of controversy: Whether increasing the number of eggs that can be
obtained from ovarian stimulation is of value, and whether there are pre-
cursor cells within the adult ovary that could become mature eggs.
Growing points: There is increasing use of donated eggs by older women
to enhance their chances of conception. The storage of frozen eggs for
potential use later in life is also becoming more common.
Areas timely for developing research: Understanding of growth initiation of
follicles and development of an artificial ovary may lead to the ability to
affect fertility and reproductive lifespan.
Key words: oocyte quality, reproductive ageing, elective oocyte banking, artificial gametes
Introduction
Recognition of the fundamental importance of the egg,
or more accurately the oocyte, to reproduction is encap-
sulated in the phrase ‘ex ovo omnia’, represented on the
frontispiece of William Harvey’s ‘Exercitationes de
Generatione Animalium’ (1651). The central, indeed
limiting, role of the oocyte is of ever growing
importance in the face of changes both in society
and with developments in medical technology. The
societal changes are most importantly the ongoing
trend for later child birth in developed societies,
and as a direct result of the growing number of
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women in their later reproductive years wishing to
start or complete their families. This has resulted in
a growing reliance on medical technology to pro-
vide solutions to address the underlying decline in
female fertility with age. This gives an added dimen-
sion to the dramatic growth in recent years in com-
mercial reproductive medicine services in the UK,
Europe and worldwide. In the UK this increase is,
at least in part, driven by the very limited provision
of assisted reproduction by the National Health
Service.
The key biological process underpinning this field
is that in humans, ovarian development occurs dur-
ing fetal life, with the basis for a woman’s fertility
and reproductive lifespan laid down before she is
born. In the early weeks of development the ovary
contains proliferating primordial germ cells (PGCs)
but their number is constrained by commitment to
meiotic division, which starts in the fourth month of
pregnancy.1 This change from germ cell division by
mitosis to meiosis, which precludes further prolifer-
ation, limits the total number of oocytes that can be
formed. Following this step, the clusters in which the
early oocytes have been developing break down, sep-
arating into individual oocytes which associate with
surrounding somatic cells to form the pool of primor-
dial follicles (Fig. 1). This is accompanied by exten-
sive germ cell death, with the majority of oocytes
being lost. Primordial follicles are the fundamental
developmental unit of the human ovary and consist
of a single oocyte which is now arrested in early mei-
osis, surrounded by a single layer of flattened somatic
cells and constitute what is known as the ‘ovarian
reserve’, the non-growing pool of follicles from which
all follicle growth and thus both ovarian endocrine
activity and fertility derive. Development from this
pool is a continuous process and activation of a small
proportion of primordial follicles occurs as soon as
follicles are formed thus leading to a depletion of the
reserve with time.2
While all follicles that start to grow during child-
hood are destined to degenerate, the activation of
the neuroendocrine axis at puberty will provide the
support for further growth and hormone
Fig. 1 Illustration of primordial follicle development and subsequent growth through preantral and antral stages to the point of
ovulation. Primordial germ cells (PGCs) proliferate forming nests, and then enter meiosis. Nest break down forming primordial
follicles, which are the non-growing state. A number of these start to grow each day, progressing through the stated phases dur-
ing which they become gonadotrophin sensitive and then dependent. In the final preovulatory phase, the ovulation-inducing LH
surge causes the oocyte to reenter meiosis and be released from the follicle. The sizes given are of the oocyte, not the follicle,
showing how that also grows dramatically during this process.
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production of a proportion of these follicles. This is
under stimulatory control from gonadotropin hor-
mone releasing hormone from the hypothalamus of
the brain, which results in increased secretion of the
hormones luteinising hormone and follicle stimulat-
ing hormone from the pituitary. While the early
stages of follicle development are primarily under
local paracrine control from growth factors pro-
duced by the somatic cells in the local environment
and other nearby growing follicles,3 later stages are
increasingly sensitive to and then dependent on LH
and FSH secretion, whose subtle variation across
the menstrual cycle results in the selection of just
one follicle per month for ovulation.4 Throughout
life, the great majority of follicles become atretic at
some point during their development, with 1 in per-
haps 300 that start to grow per month resulting in
ovulation and thus the potential for pregnancy in a
women of reproductive age. Ultimately, menopause
occurs when the number of follicles remaining in
the ovary is too small to support sufficiently the
process of selection for dominance and ovulation
each month. This results in the end of the potential
for fertility, and a major fall in estrogen production,
as that is determined by the presence of large grow-
ing follicles, inducing the vasomotor and other
symptoms of the menopause.
For as long as a woman continues to ovulate,
there is the potential for conception each month but
the chance of this declines substantially with age.
This is accompanied by an increase in the chance of
miscarriage of early pregnancies, with both these
factors reflecting declining egg quality.5 This age-
related decline is attributed to the onset of meiosis
during fetal life, discussed below, with the conse-
quent need to maintain chromosomal integrity for
decades thereafter. In the face of these factors, there
have been substantial changes in the age distribu-
tion of women giving birth in recent decades, with
recent the UK data showing steady increases in the
number of births from women in their thirties and
indeed, forties over the last 30 years with equivalent
decreases in women in their teens and early twen-
ties.6 Indeed, in 2015 the birth rate in women aged
40 and over was greater than that for women under
the age of 20. While there is much to celebrate in
the falling teenage pregnancy rate, there seems little
likelihood of any change in the increasing wish of
women in their later thirties and early forties to
have a baby, and indeed to start rather than com-
plete their family at those ages. While there are
many important social and cultural aspects to this,
we will consider only what medical technology may
be able to contribute.
The importance of entry into meiosis preventing
further germ cell proliferation during fetal life has
been mentioned above. While therapeutic interven-
tion in this process seems impossible at this point, it
is also relevant that there is growing evidence of the
importance of the intrauterine environment to sub-
sequent adult health, and it seems highly likely that
this will apply to reproductive function as well as
other areas. An example of where intrauterine
exposures are now established to have a role in
reproductive development is the evidence implicat-
ing analgesic exposure during pregnancy to abnor-
mal male reproductive function such as testicular
maldescent. In utero exposure to smoking has also
been implicated as a potential factor affecting germ
cell development in both males and females. Recent
data suggest that analgesic exposure in utero may
also affect ovarian germ cell development.7 The key
molecular processes involved in early meiosis also
have implications for adult oocyte quality.8 The
correct formation of crossovers during meiotic
recombination is required to reduce the chance of
subsequent chromosomal missegregation. It is
essential that sister chromatids are held together
until meiosis resumes, which is not until the time of
ovulation, thus potentially decades after the onset
and then early arrest of the early stages of meiosis.
This chromatid cohesion is mediated by cohesin
rings. These are established during fetal life during
early meiosis, and there is evidence that they cannot
subsequently be topped-up or replenished, and this
their correct number and function appears neces-
sary for the preservation of egg quality through the
reproductive years. Early loss of these cohesin rings
is thought to be the main cause of oocyte aneu-
ploidy, which is a key cause of embryo loss and
miscarriage.8 While much of this data derives from
animal models, there is some evidence to support its
3Being a good egg in the 21st century, 2018
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relevance in human oocytes as well. A reduced
number of mitochondria in the oocyte, has also
been proposed as a cause of reduced oocyte quality,
with therefore the potential for benefit from supple-
mentation. This has been confirmed in a pig model,
with improved embryo development following
mitochondrial supplementation of oocytes with
low, but not normal, numbers of mitochondria.9
The next key stage in optimising the number of
eggs potentially available would be through increas-
ing the number of primordial follicles that start to
grow, by analogy opening the tap on the supply of
growing follicles. Understanding of the details of
how primordial follicle activation occurs is still lim-
ited although some essential biochemical pathways
have been clearly demonstrated to be implicated.10
It is at least theoretically possible to increase the
activity of these pathways thus causing increased
follicle activation but in vitro experiments thus far
indicate that this is likely to be associated with a
disruption in the tightly coordinated development
of the oocyte in its surrounding granulosa cells,
with potential loss of quality.11 More tractable are
the later stages of follicle development, and indeed
supplementing FSH concentrations to prevent fol-
licle atresia is the basis for the well-established
ovarian stimulation protocols used for IVF. There is
currently much interest clinically in whether alter-
native hormonal approaches such as the use of
androgens may increase the supply of early growing
follicles and thus allow more to progress through to
stages at which gonadotrophin stimulation regi-
mens will support further development to mature
stages.12
An alternative strategy to increase the number of
oocytes is to activate and grow large numbers of
immature oocytes to maturity in vitro.13 These tech-
niques would be particularly useful in the context
of fertility preservation, which is the storage of
oocytes, embryos or specifically relevant here of
ovarian tissue in women prior to fertility-damaging
treatment for conditions such as cancers.14 The
preservation and restoration of female fertility fol-
lowing chemotherapy by cryopreservation and
transplantation of ovarian tissue has now resulted
in over 100 live births worldwide15 and whilst the
success of this strategy has given tangible hope to
patients of conceiving and bearing their own child
there remains a risk of reintroduction of the cancer,
which means some patients could not be considered
for this procedure.
Such patients might also benefit from advances
in in vitro growth of follicles and maturation sys-
tems designed to support follicle development from
the early and more advanced stages, to produce
mature oocytes capable of fertilisation.16,17 A focus
of research has been on obtaining in vitro grown
oocytes either starting from the primordial stage of
follicle development within ovarian fragments16–18
or from isolated growing follicles (preantral folli-
cles) in vitro.19,20 A proportion of human oocytes
grown from primordial stages are able to resume
meiosis and reach Metaphase II (the stage at which
fertilisation happens) thus demonstrating meiotic
maturity.17 Whilst this source of oocytes is promis-
ing, there is still a great deal of work required to
determine how normal in vitro grown oocytes are.
More futuristic sources for obtaining human
oocytes are the creation of so called ‘artificial’ or
in vitro grown gametes from embryonic stem cells,
from induced pluripotent stem cells, or from
endogenous cells within the ovary that have the
potential to become oocytes, often called oogonial
or germline stem cells.21,22 Putative human oogo-
nial stem cells have been isolated from adult human
ovaries23,24 and these cells have some potential to
form oocyte/follicle like structures in vitro. The con-
cept that women are born with a finite number of
eggs has been a cornerstone of reproductive biology
for the last 60 years, but has now been charged by
the possible existence of these cells within the adult
ovary, that may have the potential to form mature
oocytes. Since the initial descriptions of oogonial
stem cells,25,26 there has been substantial contro-
versy as to whether they may or may not indeed
exist, and even if they do, what might be their
development potential. Only very few groups have
successfully isolated these cells, but if confirmed
they would have very substantial therapeutic appli-
cations in potentially allowing the formation of new
oocytes, potentially of high quality as they would
not have been subject to the normal long wait
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between formation and later development. Any sig-
nificant physiological role as a contributor to post-
natal ovarian function, however, seems very unlikely
at present. Oocyte development in the mouse can be
recapitulated in vitro starting from both PGCs or, in
experiments even more removed from normal physi-
ology, from induced pluripotent stem cells, which can
become immature oocytes under appropriate condi-
tions with those oocytes going on to produce viable
and fertile offspring.27,28
Obtaining oocytes in this way could alleviate the
need for donor eggs and allow women who cannot
produce mature oocytes the chance of having their
own genetic offspring, although this remains a dis-
tant goal at present. The development of these types
of techniques would also allow insights into the
basic science of oogenesis, folliculogenesis and mei-
osis as well as providing the potential for new
assisted reproductive technologies. These methods
remain experimental and the lack of successful clin-
ical translation is due in part to the exquisite sensi-
tivity and complexity of follicle maturation in large
mammals. Before clinical application can ever be
realised appropriate testing for epigenetic and mei-
otic normality of in vitro grown or derived oocytes
will be required.
In recent years, a steady accumulation of work has
been published demonstrating an alternative strategy
to in vitro growth or transplant of potentially cancer-
infected tissue by creating an ‘artificial ovary’. The
concept of the artificial ovary is of semi-solid three-
dimensional scaffold structure capable of supporting
the development and maturation of ovarian cells
seeded into or onto its surface whilst also supporting
endocrine function of the developing follicles. This
involves utilising supportive matrices capable of being
seeded with isolated ovarian follicles (that may have
been individually frozen-thawed), and transplanting
these composites into the pelvic cavity. Encapsulating
matrices for immature follicle development have been
devised from a number of biomaterials including agar-
ose,29 alginate,30 gelatin31, fibrin32 and aim to repli-
cate the physiological norms of an endogenous ovary
as closely as possible. The majority of this work has
been conducted using mouse models but is encour-
aging with structures capable of supporting the growth
and maturation of murine primordial follicles and the
birth of live pups to ovariectomised mice after surgical
placement of artificial implants. Whilst these bioengin-
eering achievements are remarkable, the length of time
necessary for immature follicles to develop is very dif-
ferent to that in higher animals and there are concerns
about the ability to ‘upscale’ and translate findings for
clinical application.
A more realistic option for the foreseeable future
is the development of both the technology and clin-
ical services for freezing eggs at a young age for
later use. The development of oocyte vitrification in
recent years has dramatically improved the survival
of frozen eggs and indeed vitrified oocytes can have
the same developmental competence as fresh ones.
Vitrification is ‘flash freezing’ involving very rapid
temperature changes, which prevent the formation
of damaging ice crystals within oocytes. This has
led to the development of services for what is often
termed ‘social egg freezing’ as well as its use for spe-
cific medical indications, such as for women with
cancer prior to chemotherapy that will markedly
impact their subsequent fertility. Controversially, it
has also been offered by some employers.33 The
slightly pejorative tone of the term ‘social egg freez-
ing’ is resulting in it increasingly being replaced by
‘elective egg banking’. There are rapid commercial
developments in this field and clearer data on likely
success rates are now becoming available highlight-
ing the impact both of the woman’s age and the
number of eggs she is able to store.34 In the UK, the
duration of storage is limited to 10 years, which is
very unhelpful to younger women, in whom of
course this approach would be most successful.
Ovarian tissue cryopreservation, developed for fer-
tility preservation for girls and young women with
cancer as discussed above, would also, at least in
theory, offer an alternative approach for women
wishing to preserve their fertility for non-medical
reasons. It does, however, require a surgical proced-
ure to remove the ovarian tissue as well as its subse-
quent replacement and thus at the moment it
appears to be used only for medical indications.15
If the number and quality of one’s own eggs is
compromised, then using someone else’s is a possi-
bility. The use of egg donation has clearly shown
5Being a good egg in the 21st century, 2018
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that egg quality is indeed the key determinant of the
decline in success rate in assisted reproduction with
age, with the chance of birth being dependent on
the age of the egg donor, not the recipient.35
Although initially used only for women who had no
oocytes of their own egg following cancer treatment
or other causes of premature ovarian insufficiency
this approach is increasingly used by premenopau-
sal but older women. It is undoubtedly a technically
very successful treatment, increasing the cumulative
live birth rate for women aged over 40 from under
10% to 30% per embryo transfer.36 The limiting
factor is often the number of women coming for-
ward as potential egg donors but in many countries
IVF clinics have been very successful in establishing
a sufficient supply of oocytes for donation, and
indeed are increasingly establishing ‘egg banks’ of
frozen oocytes so that potential recipients do not
have to have their treatment synchronised with that
of the donor. The marked differences in availability
of this by country have resulted in what is some-
times termed ‘reproductive tourism’, although that
term is increasingly replaced by ‘cross border repro-
ductive health care’.
Conclusions
In summary, therefore, there are very clear and
indeed growing issues and pressures surrounding
the need to be ‘a good egg’ in the 21st century. This
subject is at the interface of both social changes and
technological developments in reproductive medi-
cine, with this interaction providing both a drive to
progress and public debate. In the UK, there is a
very clear regulatory framework which the great
majority of those working in this field strongly sup-
ports, although its basis in primary legislation does
not readily allow for change. It seems clear that the
need for public debate will, if anything, increase in
coming years as the ability to manipulate human
reproductive function increases.
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